Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Allergan's Fishing For Deals, But Don't Expect A Big Catch

Executive Summary

Allergan PLC will use its $36bn in after-tax cash and equity from the sale of its generics business to Teva Pharmaceutical Industries Ltd. to reduce debt, buy back shares of its stock, and to acquire companies or assets, but don't expect Allergan to catch any big fish in its dealmaking net.


Related Content

Editas Deal Opens Allergan's Eyes To CRISPR Opportunities
Allergan Adds Accretive Aesthetics Assets In $2.9bn LifeCell Acquisition
Allergan 'Unusual Suspect' But Pipeline 'Hunger' A Perfect Match For Heptares
Allergan's Back In The (M&A) Saddle Again Post Pfizer Breakup
White House, Allergan Spar Over 'Un-American' Claim
It's All Off: $160bn PfizerGan Deal Collapses On Latest US Treasury Edicts
Allergan Seeks Opportunities To Dominate In Key Therapeutic Areas
With $36bn from Teva, what should Allergan buy next?
Actavis renamed as Allergan
Actavis will become Allergan to emphasize branded pharma focus


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts